Description: Agile Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, a 28-day regimen, which provides a shortened hormone-free interval; and AG890, a levonorgestrel-only contraceptive patch for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Home Page: www.agiletherapeutics.com
AGRX Technical Analysis
500 College Road East
Princeton,
NJ
08540
United States
Phone:
609 683 1880
Officers
| Name | Title |
|---|---|
| Mr. Alfred F. Altomari | Chairman & CEO |
| Mr. Geoffrey P. Gilmore | Chief Admin. Officer |
| Dr. Paul Korner M.B.A., M.D. | Sr. VP & Chief Medical Officer |
| Mr. Jason Butch | Principal Financial Officer, VP & Chief Accounting Officer |
| Matthew Riley | Head of Investor Relations & Corp. Communications |
| Mr. Robert G. Conway M.E. | Chief Corp. Planning & Supply Chain Officer |
| Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D., M.P.H. | Consultant |
| Ms. Amy Welsh | Chief Commercial Officer |
| Joseph D'Urso | Controller |
| Dr. Kathryn MacFarlane Pharm.D. | Advisor |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2457 |
| Price-to-Sales TTM: | 0.9136 |
| IPO Date: | 2014-05-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 30 |